Lumida
/RYTM
⌘K
Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

RYTM
$104.71USD+2.46%+2.51 today

MARKET CAP

7.2B

P/E (TTM)

FWD P/E

DAY RANGE

$102 – $107

52W RANGE

$75
$122

AI Summary

Stalk
Buy NowMedium

RYTM remains in a Stage 2 advancing uptrend with higher highs and higher lows riding above rising EMAs. Recent price action shows a mild pullback into the rising 9EMA, offering a lower-risk entry while momentum indicators remain healthy and volume supports the trend. Overbought conditions are moderate, making now an opportune time to buy near structural support rather than chasing further extensions.

  • Phase 3 TRANSCEND trial showed significant BMI/hunger improvements and no major safety issues; setmelanotide now FDA/EU approved
  • JPMorgan initiated coverage with an overweight rating and $145 price target, implying ~42% upside
  • P/S ratio of 31.3x far exceeds biotech peers, flagging potential overvaluation
Full analysis →

Buying

5

institutions

Selling

11

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

InstitutionActionShares HeldValueChangeChg %Weight
BI

Blackrock, Inc.

Q2 2026

SELL6.16 M683.60 M+-80.25 K+26.0%0.01%
JC

Jpmorgan Chase & Co

Q2 2026

BUY2.65 M292.18 M+1.10 M+143.4%0.02%
PA

Perceptive Advisors LLC

Q2 2026

SELL2.59 M287.16 M+-2.16 M-30.4%4.32%
JH

Janus Henderson Group Plc

Q1 2026

BUY1.84 M159.77 M+710.18 K+32.5%0.04%
CA

Citadel Advisors LLC

Q2 2026

SELL1.31 M145.36 M+-143.87 K+15.0%0.02%
WP

Woodline Partners LP

Q2 2026

SELL758.89 K84.26 M+-758.89 K-36.2%0.26%
PA

Point72 Asset Management, L.P.

Q2 2026

SELL414.21 K45.99 M+-432.59 K-37.5%0.05%
MM

Millennium Management LLC

Q2 2026

SELL316.72 K35.17 M+-135.11 K-10.5%0.01%
DF

Duquesne Family Office LLC

Q2 2026

BUYNEW203.62 K22.61 M+203.62 K+0.0%0.43%
AC

Adar1 Capital Management, LLC

Q2 2026

SELL136.16 K15.12 M+-75.29 K-17.8%0.70%
RT

Renaissance Technologies LLC

Q2 2026

SELL68.28 K7.58 M+-189.73 K-66.2%0.01%
AC

Aqr Capital Management LLC

Q2 2026

SELL59.21 K6.57 M+-71.00+27.5%0.00%
MG

Man Group Plc

Q2 2026

BUY50.79 K5.64 M+46.77 K+1512.1%0.01%
RC

Rockefeller Capital Management L.P.

Q2 2026

BUY5.95 K660.07 K+1.10 K+56.7%0.00%
BA

Balyasny Asset Management L.P.

Q2 2026

SELL0.000.00+-52.97 K-100.0%0.00%
BH

Brevan Howard Capital Management LP

Q2 2026

SELL0.000.00+-3.78 K-100.0%0.00%